Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alka-Seltzer Plus extension

This article was originally published in The Tan Sheet

Executive Summary

Quick-dissolve tablets debuting for 2003 cough/cold season contain pseudoephedrine HCl, chlorpheniramine maleate for nasal congestion, sneezing, sinus pressure and runny nose, Bayer says. Alka-Seltzer Plus Ready Relief Tabs do not contain acetaminophen, as previously reported (1"The Tan Sheet" June 23, 2003, p. 10)...

You may also be interested in...



NACDS In Brief

Bayer: Alka-Seltzer Plus Ready Release quick dissolve tablets slated to ship in early August, firm says at National Association of Chain Drug Stores Marketplace in San Diego June 8-10. New delivery form "melts in your mouth" with "no water needed," labeling notes. Tablets in blister-pack 12-count boxes contain acetaminophen and pseudoephedrine, will be indicated for nasal congestion, runny nose, sneezing and sinus pressure. Consumers are advised to take two tablets for symptom relief; flavors include cool mint and orange zest. Bayer will support the line extension with television and print ads, as well as FSI drops in October, November and December...

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Sanofi Skates To Where The Puck Is With Immunology

The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel